The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
The Lundquist Institute and Vitalex Biosciences Secure $40 Million Contract for Phase 1 Trials of Second-Generation Fungal Vaccine VXV-01.
Dec 15, 2025•6 months ago
Contract Type
contract
BiotechnologyHealth CareEducationNon Profit
Description
The Lundquist Institute and its start-up Vitalex Biosciences have received a significant contract from NIH/NIAID valued at up to $40 million to advance the development of their fungal vaccine, VXV-01, through Phase 1 trials. This funding will support the manufacturing and necessary preclinical studies for the vaccine.
Company Information
Company
The Lundquist Institute
About
The Lundquist Institute is a prominent research organization focusing on innovative biomedical and health-related discoveries. It collaborates with various partners to advance scientific knowledge and develop new therapies. The institute emphasizes the importance of translating research into clinical applications.
Predictive Intelligence
Strategic
ML-powered predictions for The Lundquist Institute's next move
